[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse APOBR

Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Note=Binds monocyte-macrophage membrane. Thought to be anchored in the membrane through an interaction with an integral membrane protein.
Domain -
Function

Macrophage receptor that binds to the apolipoprotein B48 (APOB) of dietary triglyceride (TG)-rich lipoproteins (TRL) or to a like domain of APOB in hypertriglyceridemic very low density lipoprotein (HTG-VLDL). Binds and internalizes TRL when out of the context of the macrophage. May provide essential lipids to reticuloendothelial cells. Could also be involved in foam cell formation with elevated TRL and remnant lipoprotein (RLP). Mediates the rapid high-affinity uptake of chylomicrons (CM), HTG-VLDL, and trypsinized (tryp) VLDL devoid of APOE in vitro in macrophages.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0006869 lipid transport
GO:0006898 receptor-mediated endocytosis
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0010876 lipid localization
GO:0016125 sterol metabolic process
GO:0046486 glycerolipid metabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1902652 secondary alcohol metabolic process
Molecular Function GO:0030228 lipoprotein particle receptor activity
GO:0030229 very-low-density lipoprotein particle receptor activity
GO:0038024 cargo receptor activity
Cellular Component GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:0034361 very-low-density lipoprotein particle
GO:0034362 low-density lipoprotein particle
GO:0034385 triglyceride-rich lipoprotein particle
GO:0042627 chylomicron
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-8855121: VLDL interactions
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between APOBR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of APOBR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of APOBR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1790.553
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.260.797
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1160.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9630.0442
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0760.624
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8240.758
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2550.577
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4560.646
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0550.959
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3770.234
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1890.492
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1680.294
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of APOBR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.811.8120.427
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APOBR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APOBR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APOBR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APOBR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of APOBR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between APOBR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAPOBR
Nameapolipoprotein B receptor
Aliases APOB48R; APOB100R; apolipoprotein B48 receptor; apolipoprotein B100 receptor; apoB-48R; apolipoprotein B-100 ......
Chromosomal Location16p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting APOBR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting APOBR.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141